The U.S. Food and Drug Administration sent a warning letter to St. Jude Medical Inc. (NYSE: STJ) that cites the device maker for improperly promoting a cardiac-ablation system.
St. Jude on its website promoted its Epicor cardiac-ablation system for use in treating atrial fibrillation, an irregular heartbeat that can result in stroke. However, the system has only received FDA approval to be used in ablation, or destruction, of diseased heart tissue during surgery.
St. Jude has received the go-ahead from the FDA to investigate the device’s use in treating atrial fibrillation, but that’s a far cry from government approval to sell and market the device.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In addition to the unapproved claims on St. Jude’s website, the FDA found similar problems with marketing brochures and materials aimed at physicians.
The FDA gave St. Jude 15 days to provide written documentation of what it’s doing to correct the problem. The company told the Associated Press that it’s “working diligently to address the points raised in the warning letter and to resolve the FDA’s concerns.”
The warning letter was dated April 23, but first posted to the FDA’s website Tuesday.
In its most recent quarterly report, St. Jude cited an investigation by the U.S. Department of Justice into similar false marketing claims of the Epicor device. St. Jude said it received a letter from the DOJ regarding the matter in October 2008. The company said it’s cooperating with the investigation.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
St. Jude acquired Epicor Medical Inc. and its eponymous device in 2004 for $185 million.
